Daily non-political popular news in brief.

12-month study demonstrated tolerability and efficacy of Daytrana

Shire plc announced that Daytrana, the first and only non-oral medication approved for treatment of ADHD in children aged 6 to 12 years, provided significant improvement in symptom control and tolerability, according to results of a 12-month open-label study presented at the American Psychiatric Association annual meeting.

Read more »

Keywords: 12-month, study, demonstrated, tolerability, efficacy, daytrana, month

« Previous | Next »

Similar news on "12-month study demonstrated tolerability and efficacy of Daytrana":

1. Long-term 12-month safety data on ADHD patch DAYTRANA
   10-25-2007 · EurekAlert!
   Shire plc announced that DAYTRANA (methylphenidate transdermal system), the ADHD patch, provided significant ADHD tolerability and symptom control improvement in children aged 6 to 12 years, according to data from a 12-month study presented today at a major scientific and educational meeting of child and adolescent psychiatrists.
   Similar news · Read more »
   
2. New long-term data analyses for Bifeprunox show favorable effects vs. placebo
   05-22-2007 · EurekAlert!
   Solvay Pharmaceuticals, Inc., Wyeth Pharmaceuticals, a division of Wyeth, and Lundbeck A/S presented clinical study results on bifeprunox, an investigational treatment for adult patients diagnosed with schizophrenia, today at the 2007 annual meeting of the American Psychiatric Association. New analyses of six-month data in stabilized adult patients with schizophrenia from a double-blind, placebo-controlled study demonstrated that bifeprunox maintained stability vs. placebo and displayed a favorable weight and lipid profile comparable with placebo.
   Similar news · Read more »
   
3. High school theater program helped strengthen adolescents' emotional development
   07-20-2007 · EurekAlert!
   A study conducted among adolescents in a high school theater program demonstrated how teens learned about how to employ positive emotions to motivate their work. Students also used strategies to manage their own and others' negative emotions. The research was conducted through interviews with the students during a three-month period of rehearsals. This study demonstrates how schools and programs can support the development of "emotional intelligence" of adolescents.
   Similar news · Read more »
   
4. VYVANSE trial in adult ADHD demonstrated significant efficacy within 1 week of daily treatment
   10-25-2007 · EurekAlert!
   Shire plc, the global specialty biopharmaceutical company, announced that a phase 3 study demonstrated adults experienced significant improvements in ADHD symptom control within one week of treatment with once-daily VYVANSE, the first prodrug stimulant.
   Similar news · Read more »
   
5. Study evaluates the effectiveness of Aripiprazole in adolescents with schizophrenia
   05-23-2007 · EurekAlert!
   In a study in adolescents (13-17 years) with schizophrenia, the atypical antipsychotic Abilify demonstrated significant improvement compared to placebo on the primary efficacy endpoint, Panns Total Score.
   Similar news · Read more »
   
6. Cell death suppression increases efficacy of M2 vaccines
   01-15-2008 · EurekAlert!
   Scientists from Cure Lab, Inc. in collaboration with Boston University School of Medicine published new findings indicating that unmodified M2 may have a negative effect on anti-influenza vaccination. The researchers also demonstrated how this detrimental effect of M2 can be eliminated, thereby allowing any future M2-containing vaccine to be both broadly protective as well as safe. This study appears in the Jan. 16 issue of the online journal PLoS ONE.
   Similar news · Read more »
   
7. Deficient regulators in the immune system responsible for type 1 diabetes
   01-24-2008 · EurekAlert!
   The reduction in the regulating capacity of some regulators of the immune system (called CD4+Treg cells,) seems to play a critical role in the onset of type 1 diabetes, as demonstrated in the latest study by Dr. Ciriaco Piccirillo, a researcher in the department of microbiology and immunology at the Research Institute of the McGill University Health Center and the principal investigator for this project. This study was published this month in the journal Diabetes.
   Similar news · Read more »
   
8. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
   09-18-2007 · EurekAlert!
   Provecta demonstrated minimal side effects, significant efficacy and bystander effect on melanoma tumors in stage III patients.
   Similar news · Read more »
   
9. New Analyses of long-term LIALDA (mesalamine) data presented at ACG
   10-15-2007 · EurekAlert!
   Post-hoc and other analyses of secondary endpoints of a long-term safety and tolerability study of Shire plc's ulcerative colitis drug LIALDA (mesalamine) provide further data on LIALDA in patients with mild to moderate ulcerative colitis. These analyses of LIALDA's 303 trial, a long-term, Phase III, open-label 12-14 month extension study, are being presented this week at the American College of Gastroenterology meeting in Philadelphia.
   Similar news · Read more »
   
10. Study demonstrated AMITIZA (lubiprostone) showed efficacy
    10-23-2006 · EurekAlert!
    Results of a secondary analysis of two pivotal studies were presented today at the 71st Annual Meeting of the American College of Gastroenterology (ACG), and showed that 60 percent of patients treated with AMITIZA (TM) (lubiprostone) experienced a spontaneous bowel movement (SBM) within 24 hours of treatment, and 80 percent experienced a SBM within 48 hours of treatment.
    Similar news · Read more »